Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 401 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
Interventions
[18F]MK-0947
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

A Multi-modality Imaging Assessment of Chemobrain

NCT00708045
Conditions
Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1 Interventional Results available

PET Imaging and Bariatric Surgery

NCT00801827
Conditions
Obesity, Morbid
Interventions
F-18 (fallypride)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

NCT04251130
Conditions
Mild Cognitive Impairment
Interventions
2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Central Nervous System Cancer, Brain Metastases
Interventions
[C-11]-CS1P1, Brain MRI
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Other · Drug · Procedure
Lead sponsor
Daniel M. Spielman
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Duarte, California
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

NCT00598286
Conditions
CB1, Cannabinoid, PET, Brain Imaging
Interventions
[18F]FMPEP-d2
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cancer of the Prostate
Interventions
C-11 Choline PET Imaging
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Chronic Traumatic Encephalopathy
Interventions
florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Completed No phase listed Observational Results available

Brain Nicotine Receptor Density in Veteran Smokers

NCT01721473
Conditions
Positron Emission Tomography
Interventions
positron emission tomography scan
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
San Diego, California • West Los Angeles, California
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy Volunteers
Interventions
Brain Imaging (PET), Aterial Line, Blood Sampling
Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Enrolling by invitation Phase 2Phase 3 Interventional Accepts healthy volunteers

Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder

NCT05015881
Conditions
Alcohol Use Disorder (AUD), Alcohol Drinking
Interventions
Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", FDG
Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania